MW Medical Appoints Sales and Marketing Executives
Monday April 26, 6:00 am Eastern Time
Company Press Release
SOURCE: MW Medical Inc.
SCOTTSDALE, Ariz., April 26 /PRNewswire/ -- Paul E. Banko, President and CEO, MW Medical Inc. (OTC Bulletin Board: MWMD - news), has announced the appointment of two key executives effective immediately.
Mitch DeShon has been appointed Vice President, Sales of MW Medical Inc. Mr. DeShon was most recently National Sales Director for ESC Medical Systems and has had extensive experience in the aesthetic and surgical laser markets. DeShon graduated from San Diego State University with a BA in Business and then gathered sales, marketing, and management experience with Sony Hospital Digital Systems, Sherwood Medical, and Luxar Corporation.
Mitch DeShon will be based at our MW Medical California offices and will start organizing a national distribution network of independent sales agents and distributors who have shown interest in selling MW Medical's proprietary product line. The company expects to have at least 60 dedicated agents contacting potential customers during 1999. The company anticipates 510(K) approval in 1999 for hair removal and will be filing additional applications to the FDA for other uses, including telangiectasia (spider veins), orbital facial wrinkles with non-ablative microwave treatment, and stretch marks.
The company also appointed Kenneth B. Karasiuk, Vice President, Operations. Ken has most recently managed his own firm, Twin Med, that distributed and marketed lasers for various cosmetic and medical uses. Twin Med was one of ESC Medical System's most active west coast distributors. Mr. Karasiuk has been in the hair removal industry for 15 years and has extensive contacts throughout North America in the cosmetic surgery field.
Karasiuk will be responsible for distribution, customer service, technical support, marketing, and promotion and along with DeShon will determine and execute the marketing plan.
MW Medical has recently filed a 510(K) application for hair removal and will add other indications as clinical trials are completed.
Statement Under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product acceptance, economic, competitive, governmental, results of litigation, technological and/or other factors, which are outside the control of the Company.
SOURCE: MW Medical Inc. |
